EcoR1 Capital’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

EcoR1 Capital’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200,000	Closed	-$2.03M	–	69
2023 Q1	$2.03M	Hold	200,000	–	–	0.07%	47
2022 Q4	$2M	Hold	200,000	–	–	0.06%	56
2022 Q3	$2M	Hold	200,000	–	–	0.06%	60
2022 Q2	$1.98M	Hold	200,000	–	–	0.07%	59
2022 Q1	$1.97M	Hold	200,000	–	–	0.06%	68
2021 Q4	$1.95M	Hold	200,000	–	–	0.06%	59
2021 Q3	$1.96M	Hold	200,000	–	–	0.07%	54
2021 Q2	$1.97M	Hold	200,000	–	–	0.07%	57
2021 Q1	$2M	Buy	+200,000	New	+$2.05M	0.09%	55

EcoR1 Capital's EUCR Position: Q2 2023 in Review

EcoR1 Capital sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q2 2023, closing a stake of 200,000 shares — an estimated $2.03M sold.

EcoR1 Capital first reported a position in EUCR in Q1 2021 and held it in 9 quarters. The position peaked at $2.03M in Q1 2023. 0 funds tracked by Wall St. Rank hold EUCR as of Q2 2023.

EcoR1 Capital reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q2 2023 after selling out during the quarter.
EcoR1 Capital sold 200,000 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q2 2023, an estimated $2.03M.
EcoR1 Capital first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 9 quarters.
EcoR1 Capital's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $2.03M in Q1 2023.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q2 2023.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.